tbuckley/cabot-search huggingface dataset:
Looking after children.
Authors: J Woodrow, W Donohoe
Journal: BMJ (1968)

which appears in the B.M.7.this week at page 139 is a further contribution to the natural history and prevention of Rh- immunization in pregnancy.Their work emphasizes that primary immunization occurs as a result of the first preg- nancy (though no antibody can be detected) and that a very few foetal cells passing over during the next Rh-positive, ABO-compatible pregnancy will lead to the rapid appearance of anti-Rh antibodies.They also provide more evidence that immunization, both primary and secondary, may follow from the entry of less than 0.1 ml.foetal blood into the maternal circulation, representing a foetal cell score of 0-4.This was more often the case at the end of the second Rh-positive, ABO-compatible pregnancy than after the first.Anti-D gammaglobulin is now in routine use in the United Kingdom for preventing Rh-immunization, but because supplies are limited its use has been restricted to Rh-negative primiparae who give birth to an Rh-positive, ABO-compatible infant and in whom the foetal red cell score is 5 or more, this representing 0.2 ml. or more of foetal blood.But recently the Ministry of Health has recommended that treatment should now be based on finding any foetal cells.The report of Woodrow and Donohoe shows that the former criterion of selection leaves unprotected two-thirds of the cases in which anti-Rh antibodies might be expected to develop after the next Rh-positive, ABO-compatible pregnancy, these cases having foetal cell scores of 0-4.It seems, therefore, that the foetal cell score shortly after delivery is not a reliable way of selecting all patients for treatment, since a significant number of women who subsequently become immunized have no detectable foetal cells.Furthermore, the method of detect- ing and counting foetal cells can present difficulties in inexperienced hands, yet many hospital laboratories are now burdened with the additional task of providing this service.It is becoming apparent that to protect the maximum number of patients at risk the best policy would be to give anti-D to all Rh-negative women who give birth to an Rh-positive, ABO-compatible infant and in whom antibodies have not been detected, regardless of parity or foetal cell score.Even patients with ABO-incompatible infants have some, though a much smaller, risk of becoming immunized, and a case exists for treating them as well.It is probably also wise to treat all previously unimmunized Rh-negative women who abort, since it is usually not possible to ascertain the blood group of the abortus.The practicability of such a policy will obviously depend on the supply of anti-D gammaglobulin of suitable potency, and until there is enough some degree of selection of cases for treatment is necessary.It is hoped that enough anti-D will shortly be available to meet the needs of all Rh-negative primiparae at risk.Finally, there is the problem of what constitutes an effective dose of anti-D gammaglobulin, and on this question the Medical Research Council is at present conducting a trial.
THE DIAGNOSTIC AND THERAPEUTIC VALUE OF LUMBAR PUNCTURE
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Affluent drowning victims; manacled minds
Authors: A. G. Gordon
Journal: JAMA (1988)

<h3>To the Editor.—</h3> Dr Orlowski<sup>1</sup>endorses the claim by Bolte et al<sup>2</sup>that 66 minutes is the longest submersion followed by full neurological recovery on record. However, Rowland Jackson<sup>3</sup>reviewed several reports claiming much longer intervals. They contain some surprising and convincing details, some confirmed by later accounts. Cold water or ice was often implicated. Consciousness was retained.<sup>4</sup>Several survivors experienced excessive noise while immersed, either tinnitus or amplified environmental noises, a fact known to Shakespeare.<sup>4</sup>It is hard to see why this symptom would be mentioned by frauds or malingerers or be invented in fanciful accounts. For those who will scoff, Jackson has a Warning<sup>3</sup>: <i>Credulity</i>is fatal to Truth, yet we observe in the Minds of some Men, an arrogant and presumptuous<i>scepticism</i>, which, admitting nothing but what is easy to the Conception of its possessors, is no less prejudicial to the
Abstract P081: Markers of Endothelial Function and Peripheral Arterial Disease among Women
Authors: Sona Rivas-Tumanyan, Kenneth J Mukamal, Jennifer K Pai, Kaumudi J Joshipura
Journal: Circulation (2013)

Introduction: Markers of endothelial function may be associated with increased risk for cardiovascular disease; however, prospective data for peripheral arterial disease (PAD) are limited. We evaluated the hypothesis that serum markers of endothelial dysfunction are associated with an increased risk of PAD among women. Methods: We conducted a nested case-control study within an ongoing prospective cohort of U.S. female nurses (Nurses’ Health Study). Among 32,826 NHS participants who provided blood samples in 1989-1990, after excluding those who had myocardial infarction, coronary heart disease, stroke, or carotid artery surgery prior to the PAD diagnosis, we included all incident PAD cases that occurred between 1990 and 2008 and were confirmed by medical records. Each case was individually matched with three eligible controls using risk-set sampling, by age, smoking, date of blood draw, and fasting status. We evaluated the association between serum levels of soluble intercellular adhesion molecule (ICAM-1), E-selectin, and the risk of PAD, using conditional logistic regression analysis. Results: Complete biomarker data from 1990 was available for 144 cases and 431 controls. After accounting for matching factors, baseline ICAM-1 levels were associated with higher risk of PAD (RR for highest (T3) vs. lowest (T1) tertile=1.75, 95% CI: 1.05-2.90). The association was attenuated and no longer significant (RR T3 vs. T1=1.37, 95% CI: 0.75-2.49) after adjusting for serum levels of HDL and LDL-cholesterol, family history of myocardial infarction, relative weight, reported aspirin and cholesterol-lowering medication use, hypertension and diabetes diagnoses, physical activity, and pack-years of smoking. Additional adjustment for CRP levels further attenuated the relative risk (RR T3 vs. T1= 1.24, 95% CI: 0.67-2.29). We did not observe any significant association between baseline E-selectin levels and the risk of PAD (multivariate- and CRP-adjusted RR T3 vs. T1=0.93, 95% CI: 0.54-1.59). Conclusions: There was no association between ICAM-1 and E-selectin and subsequent PAD in this cohort of U.S women.
Endocrinology
Authors: Nelson B. Watts
Journal: JAMA (1994)

Two prospective studies reported in 1993 provided an answer to a controversial question: Would intensive treatment of patients with insulin-dependent diabetes mellitus (IDDM) reduce the development or progression of microvascular complications? The Stockholm Diabetes Study,<sup>1</sup>which began in 1982, involved 102 patients (mean age, 30 years; mean duration of diabetes, 17 years) who were followed up for 7.5 years. The Diabetes Control and Complications Trial (DCCT),<sup>2</sup>sponsored by the National Institutes of Health, Bethesda, Md, and conducted at 29 centers in the United States and Canada, involved 1441 patients in two cohorts: a primary prevention group (patients without apparent microvascular complications at entry; mean age, 27 years; mean duration of diabetes, 2.6 years) and a secondary intervention group (patients with mild retinopathy at entry; mean age, 27 years; mean duration of diabetes, 8.7 years); the patients in the DCCT were followed up for an average of 6.5 years.
Your Inner Child of the Past.
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Figure 1
Journal: JAMA Network Open (2020)

Yannan Yu, MD; Yuan Xie, MS; Thoralf Thamm; Enhao Gong, PhD; Jiahong Ouyang, MS; Charles Huang, BS; Soren Christensen, PhD; Michael P. Marks, MD; Maarten G. Lansberg, MD; Gregory W. Albers, MD; Greg Zaharchuk, MD, PhD
Author's Name Misspelled
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOOK REVIEW
Authors: I. MAGRATH
Journal: JNCI Journal of the National Cancer Institute (1994)

BOOK REVIEW Get access The Molecular Basis of Blood Diseases, 2nd Edition . G. Stamatoyannopoulos , A. W. Nienhuis , H. Vannus , eds. W. B. Saunders : Philadelphia , 1993 , 1010 pp, illus. $175. ISBN 0-7216-4735-9 IAN MAGRATH, M.D. IAN MAGRATH, M.D. Pediatric Branch Division of Cancer Therapy National Cancer Institute Bldg10, Rm. 13N240 Bethesda, MD 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 20, 19 October 1994, Pages 1552–1553, https://doi.org/10.1093/jnci/86.20.1552 Published: 19 October 1994
Stevens-Johnson syndrome associated with Mycoplasma pneumoniae infection
Authors: O. F. Sieber
Journal: JAMA (1967)

MUCOCUTANEOUS DISEASES, such as Stevens-Johnson syndrome and Behcet's syndrome, have been attributed to a variety of inciting factors<sup>1,2</sup>including drug allergies, infectious agents, and foods. The most prevalent view has been that some form of hypersensitivity results in the typical mucocutaneous lesions. The seasonal nature of this illness in the Denver area, however, has suggested an infectious etiology, but no single infectious agent has been consistently demonstrable with this disease. Equally impressive has been the frequent finding of pneumonitis in reports of Stevens-Johnson syndrome.<sup>3</sup> In 1964, Ludlam et al<sup>3</sup>suggested an association of<i>Mycoplasma pneumoniae</i>with Stevens-Johnson syndrome. Using a complement-fixing (CF) antibody technique as a serological screening test, they consistently noted a high level of antibody in children with various clinical manifestations of this syndrome. For these reasons we have searched for<i>M pneumoniae</i>in patients with Stevens-Johnson syndrome. In the following report a young soldier
Books Received
Journal: JNCI Journal of the National Cancer Institute (1996)

radiologists would not completely agree with Dr. Logan-Young's protocols, none would dispute that her descriptions of how to perform these procedures are clear and well illustrated and are based on vast experience.Chapter 10 provides a step-by-step approach to mammographic and sonographic preoperative localization techniques.It also discusses special measures necessary for Dr. Logan-Young's patients, all of whom after the localization procedure must be transported from her office to operating rooms at one of several local hospitals, often located miles away.Chapter 11 describes the potential advantages of digital mammography, which Dr. Logan-Young believes will start to replace screen-film mammography by the end of the century.She thinks that magnetic resonance imaging may have some value for staging, although its lower resolution, higher false-positive and falsenegative rates, higher costs, and limited availability will restrict its value in diagnosis and probably preclude any screening function.Chapter 12 contains an especially informative discussion of Dr. Logan-
Potential Health Effects of Indoor Radon Exposure
Authors: Edward P. Radford
Journal: Environmental Health Perspectives (1985)

Radon-222 is a ubiquitous noble gas arising from decay of radium-226 normally present in the earth's crust. Alpha radiation from inhaled short-lived daughters of radon readily irradiates human bronchial epithelium, and there is now good evidence of excess risk of lung cancer in underground miners exposed to higher concentrations. In homes, radon levels are highly variable, showing approximately log-normal distributions and often a small fraction of homes with high concentrations of radon and radon daughters. Factors affecting indoor concentrations include type of bedrock under dwellings, house foundation characteristics, radon dissolved in artesian water, and ventilation and degree of air movement in living spaces. Despite much recent work, exposures to radon daughters by the general public are not well defined. From application of risk assessments in miners to home conditions, it appears that about 25% or more of lung cancers among nonsmokers over the age of 60, and about 5% in smokers, may be attributable to exposure to radon daughters at home. It may be necessary to take remedial action to reduce this hazard in those dwellings with elevated levels of radon, and new construction should take account of this problem.
Perinatal outcomes in the pregnancies of asthmatic women: a prospective controlled analysis.
Authors: M Schatz, R S Zeiger, C P Hoffman, K Harden, A Forsythe, L Chilingar, B Saunders, R Porreco, W Sperling, M Kagnoff
Journal: American Journal of Respiratory and Critical Care Medicine (1995)

Prior studies have found an increased incidence of adverse perinatal outcomes of pregnancies in asthmatic mothers, but these studies have been poorly controlled for asthma therapy and other confounding factors. The purpose of this study was to assess perinatal outcomes in actively managed pregnant asthmatic women as compared with matched nonasthmatic controls. Using an inception cohort design, we studied a volunteer sample of 486 pregnant (< 28 wk) women with documented asthma and 486 pregnant nonasthmatic controls with normal pulmonary function. Cases and controls were matched for age, smoking status, parity, and year of delivery. Asthma was managed with step therapy to prevent acute asthmatic episodes and asthma symptoms that interfered with sleep or normal activity. Chronic hypertension was significantly more common (p = 0.007) in asthmatic subjects (3.7%) than in matched controls (1.0%). However, no significant differences in incidences of preeclampsia, perinatal mortality, preterm births, low-birth-weight infants, intrauterine growth retardation, or congenital malformations were observed in the pregnancies of the asthmatic women as compared with the matched controls. Trends were observed toward relationships between more severe asthma requiring emergency therapy or corticosteroids and increased incidences of preeclampsia and low-birth-weight infants, but these associations were not statistically significant. These data suggest that the overall perinatal prognosis for women with actively managed asthma during pregnancy is comparable to that for the nonasthmatic population.
A History of Magic and Experimental Science. Volumes V and VI: The Sixteenth Century
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
163 ASSESSMENT OF ADRENOCORTICAL RESERVE IN STABLE PATIENTS WITH CIRRHOSIS
Authors: G. Fede, L. Spadaro, T. Tomaselli, G. Privitera, J. O'Beirne, M. Garcovich, E. Tsochatzis, A.K. Burroughs, F. Purrello
Journal: Journal of Hepatology (2010)
Pharmacology
Authors: Charles H. Miller
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gout and Glycogen Storage Disease.
Authors: H. E. Holling
Journal: Annals of Internal Medicine (1963)

s1 April 1963Gout and Glycogen Storage Disease.H. E. Holling, M.D.H. E. Holling, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-58-4-719_4 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptA brother and 2 sisters, known from childhood to have had glycogen storage disease of the liver (Von Gierke's disease), survived to adult life. The course of their disorder was followed. The brother and one sister developed hyperuricemia and symptoms of gout and died from the effects of chronic renal disease at the ages of 40 and 36. The second sister remains healthy and active at the time of this account.Study of these patients and other reported cases indicates that there may be more than a chance association between gout and glycogen storage disease of the liver. Evidence from... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Philadelphia, Pa. (CS) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 April 1963Volume 58, Issue 4Page: 719-720KeywordsGlycogen storage diseasesGoutLiver diseasesRenal diseases Issue Published: 1 April 1963 PDF DownloadLoading ...
Just Words
Authors: Alexander Gode
Journal: JAMA (1965)

Before me, on an otherwise healthy-looking piece of paper, I see in my own handwriting: "[chole]ster[e] [in][ol]oid." That is what I got for being nosy about the structure of the word "steroid." I knew all along that steroids are a complex matter, but at least the word could have been simple. It seems it is not. I started out with the assumption that the word "steroid" has something to do with Greek<i>stereos</i>and the suspicion that the relationship is roundabout, for since stereos means "solid" and "-oid" suggests a deviation from the full meaning of what precedes, a steroid would be a sort-of-solid substance, which is obviously nonsense. The actual chain is this: From Greek<i>stereos</i>the French built<i>sté</i>rine by means of their suffix -<i>ine</i>. In the process they bracketed away an "e," otherwise they would have come up with<i>stéréine</i>. To this<i>stér[é]</i>ine they prefixed